Rheumatology

Top Medical News
Baricitinib delays, lowers frequency of flares in JIA
Roshini Claire Anthony, 3 days ago

In patients with juvenile idiopathic arthritis (JIA) with insufficient response to conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs), the JAK*1/2 selective inhibitor baricitinib reduced the frequency and delayed time to disease flares, according to a phase III trial presented at EULAR 2022.

Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients
Roshini Claire Anthony, 6 days ago

Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.

Change in serum marker levels tied to outcomes of RA-related interstitial lung disease
19 Jun 2022
In rheumatoid arthritis-related interstitial lung disease (RA-ILD), change over time in the levels of serum proteins, such as matrix metallopeptidase 13 (MMP13) and C-X-C motif ligand chemokine 11 (CXCL11), predict clinical outcomes, a recent study has found. The same is true for baseline clinical factors such as patient age and rheumatoid factor.
Bimekizumab shows promise across the spectrum of axial spondyloarthritis
Elaine Soliven, 18 Jun 2022
Treatment with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, significantly improved ASAS40* response rate in patients with either nonradiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS**), according to two phase III studies presented at EULAR 2022.
Antihistamines potentially beneficial for knee OA
Audrey Abella, 17 Jun 2022
The use of antihistamines was associated with reduced structural progression in knee osteoarthritis (OA), according to a post hoc analysis of two large phase III trials.
JAK inhibition with upadacitinib works well in nr-axSpA
Elvira Manzano, 16 Jun 2022
Treatment with upadacitinib improves disease activity, pain, function, and quality of life (QoL) in patients with non-radiographic axial spondyloarthritis (nr-axSpA) in a study touted as the first to evaluate a Janus kinase (JAK) inhibitor for this condition.
Familiarity with EuroLupus dosing for cSLE remains low despite uptick in use
15 Jun 2022
Paediatric specialists now use low-dose EuroLupus cyclophosphamide (CYC) more than they did a decade ago in the treatment of childhood-onset systemic lupus erythematosus (cSLE), reports a study in North America. However, familiarity with EuroLupus dosing is still low.
Special Reports
Product Highlight - Locoa
01 Dec 2021
Esflurbiprofen 40 mg transdermal patch
Product Highlight - Rinvoq
01 Dec 2021
Upadacitinib 15 mg XR-FC tab
Product Highlight - Evenity
01 Dec 2021
Romosozumab 105 mg/1.17 mL soln for inj
Conference Reports
Baricitinib delays, lowers frequency of flares in JIA
Roshini Claire Anthony, 23 Jun 2022

In patients with juvenile idiopathic arthritis (JIA) with insufficient response to conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs), the JAK*1/2 selective inhibitor baricitinib reduced the frequency and delayed time to disease flares, according to a phase III trial presented at EULAR 2022.

Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients
Roshini Claire Anthony, 20 Jun 2022

Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.

Bimekizumab shows promise across the spectrum of axial spondyloarthritis
Elaine Soliven, 18 Jun 2022
Treatment with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, significantly improved ASAS40* response rate in patients with either nonradiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS**), according to two phase III studies presented at EULAR 2022.
Antihistamines potentially beneficial for knee OA
Audrey Abella, 17 Jun 2022
The use of antihistamines was associated with reduced structural progression in knee osteoarthritis (OA), according to a post hoc analysis of two large phase III trials.
JAK inhibition with upadacitinib works well in nr-axSpA
Elvira Manzano, 16 Jun 2022
Treatment with upadacitinib improves disease activity, pain, function, and quality of life (QoL) in patients with non-radiographic axial spondyloarthritis (nr-axSpA) in a study touted as the first to evaluate a Janus kinase (JAK) inhibitor for this condition.
Sarilumab shows potential for relapsing polymyalgia rheumatica
Audrey Abella, 15 Jun 2022
The monoclonal antibody sarilumab demonstrated significant efficacy in individuals with relapsing polymyalgia rheumatica (PMR), findings from the phase III SAPHYR trial have shown.
Vitamin D, fish oil: protective against autoimmune diseases?
Audrey Abella, 13 Jun 2022
In the postintervention results of the VITAL* trial, vitamin D and marine omega-3 fatty acids (n-3 FAs) continued to demonstrate a protective effect against autoimmune diseases in older adults.